Dr. Finn on Significance of Phase III Findings of Lenvatinib in HCC

Richard Finn, MD
Published: Saturday, Sep 16, 2017



Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

This is a large, randomized, open-label phase III study of lenvatinib versus sorafenib, with a primary endpoint of noninferiority. Results showed that lenvatinib was found to be noninferior to sorafeni; additionally, lenvatinib is awaiting regulatory approval. There is buzz in the liver cancer community on how the agent would be incorporated into the landscape.

There may be subsets of patients in whom lenvatinib may perform better than sorafenib, Finn adds. It is an exciting time that, after 10 years, there may potentially be a new frontline option for these patients.

Brought to you in part by Eisai


Richard Finn, MD, associate professor of medicine at the UCLA David Geffen School of Medicine, discusses the significance of the phase III trial of frontline lenvatinib (Lenvima) versus sorafenib (Nexavar) in patients with hepatocellular carcinoma (HCC).

This is a large, randomized, open-label phase III study of lenvatinib versus sorafenib, with a primary endpoint of noninferiority. Results showed that lenvatinib was found to be noninferior to sorafeni; additionally, lenvatinib is awaiting regulatory approval. There is buzz in the liver cancer community on how the agent would be incorporated into the landscape.

There may be subsets of patients in whom lenvatinib may perform better than sorafenib, Finn adds. It is an exciting time that, after 10 years, there may potentially be a new frontline option for these patients.

Brought to you in part by Eisai

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x